Urinary Nitrite/Nitrate Concentrations and Total Antioxidant Capacity in Patients with Chronic Hepatitis C in Therapy with Interferon and Ribavirin

Abstract In this study we tried to elucidate the role of nitric oxide (NO) in chronic hepatitis C in relation to antioxidant status, since the mechanisms by which hepatitis C virus (HCV) causes cell damage and the factors underlying its resistance to therapy are not well understood. Before and after one and six months of therapy with α-interferon and ribavirin, we measured nitrite/nitrate urinary levels, total antioxidant capacity and selenium serum concentrations in 14 patients with chronic hepatitis C and in 9 healthy subjects. Before therapy, mean urinary nitrite/nitrate levels of patients were not different from those of healthy subjects, but after a 6-month treatment with α-interferon and ribavirin, these NO metabolites were higher in virologically negative patients (responders). Moreover, while no changes in selenium were observed in all patients, total antioxidant capacity was significantly higher in non-responders and well correlated with hyperuricemia (due to cell damage) observed in these subjects. Instead, uric acid decreased as free molecule in serum in responders, while we found the excretion of high NO levels as nitrite/nitrate. Our data allow us to hypothesize a role for NO as predictive of the success of therapy, since nitrite/nitrate increase in the urine of some patients precedes disappearance of the virus observed at the end of therapy.

[1]  D. Sorbi,et al.  Nitric Oxide and Chronic HCV and HIV Infections , 2001, Digestive Diseases and Sciences.

[2]  K. Shiraki,et al.  Increased plasma nitrate and nitrite concentrations in patients with hepatitis C virus infection. , 2001, Journal of hepatology.

[3]  M. Colasanti,et al.  The dual personality of NO. , 2000, Trends in pharmacological sciences.

[4]  P. Hayes,et al.  Plasma nitrites/nitrates in HCV infection and hepatocellular carcinoma , 2000, European journal of gastroenterology & hepatology.

[5]  E. Brunt,et al.  Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond , 2000, Hepatology.

[6]  C. J. Chen,et al.  Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. , 1999, American journal of epidemiology.

[7]  G. Filice,et al.  Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings , 1999, American Journal of Gastroenterology.

[8]  D. Holben,et al.  The diverse role of selenium within selenoproteins: a review. , 1999, Journal of the American Dietetic Association.

[9]  G. Brocco,et al.  A microplate-based colorimetric assay of the total peroxyl radical trapping capability of human plasma. , 1999, Analytical biochemistry.

[10]  M. Ozcan,et al.  Increased serum nitrite and nitrate concentrations in chronic hepatitis. , 1998, Journal of hepatology.

[11]  J. Prieto,et al.  Superoxide dismutase in patients with chronic hepatitis C virus infection. , 1998, Free radical biology & medicine.

[12]  D. Early,et al.  Plasma selenium in patients with cirrhosis , 1998, Hepatology.

[13]  O. Olivieri,et al.  Erythrocyte membrane lipids and serum selenium in post-viral and alcoholic cirrhosis. , 1998, Clinica chimica acta; international journal of clinical chemistry.

[14]  L. Grayson,et al.  The Total Antioxidant Capacity of Human Serum Measured Using Enhanced Chemiluminescence is Almost Completely Accounted for by Urate , 1997, Annals of clinical biochemistry.

[15]  A. Masumoto,et al.  High plasma concentrations of nitrite/nitrate in patients with hepatocellular carcinoma. , 1997, The American journal of gastroenterology.

[16]  A. Barnett,et al.  Antioxidant status in patients with uncomplicated insulin‐dependent and non‐insulin‐dependent diabetes mellitus , 1997, European journal of clinical investigation.

[17]  V. Paradis,et al.  In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. , 1997, Journal of clinical pathology.

[18]  T. Pirttilä,et al.  Unidentified antioxidant defences of human plasma in immobilized patients: a possible relation to basic metabolic rate. , 1997, Free radical research.

[19]  J. Bartolomé,et al.  Decreased nitric oxide production in chronic viral hepatitis B and C , 1997, Journal of medical virology.

[20]  K. Kröncke,et al.  Nitric oxide: cytotoxicity versus cytoprotection--how, why, when, and where? , 1997, Nitric oxide : biology and chemistry.

[21]  M. Copland,et al.  Basal nitric oxide synthesis in essential hypertension , 1997, The Lancet.

[22]  B. Halliwell,et al.  Protection Against Peroxynitrite-Dependent Tyrosine Nitration and α1-Antiproteinase Inactivation by Ascorbic Acid. A Comparison with other Biological Antioxidants , 1996 .

[23]  J. Beckman Oxidative damage and tyrosine nitration from peroxynitrite. , 1996, Chemical research in toxicology.

[24]  E. Larrea,et al.  Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C , 1996 .

[25]  A. Casadevall,et al.  Immune complexes increase nitric oxide production by interferon‐γ‐stimulated murine macrophage‐like J774.16 cells , 1995, Journal of leukocyte biology.

[26]  V. Carreño,et al.  Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-α , 1994, Digestive Diseases and Sciences.

[27]  C. Lowenstein,et al.  Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. V. Hunt,et al.  Ascorbic acid oxidation: A potential cause of the elevated severity of atherosclerosis in diabetes mellitus? , 1992, FEBS letters.

[29]  S. Tannenbaum,et al.  DNA damage and mutation in human cells exposed to nitric oxide in vitro. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Dimauro,et al.  mtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. , 1991, American journal of human genetics.

[31]  K. Yoshioka,et al.  Tumor necrosis factor α production by peripheral blood mononuclear cells of patients with chronic liver disease , 1989 .

[32]  K. Ingold,et al.  The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. , 1987, Biochimica et biophysica acta.

[33]  G. Mengozzi,et al.  Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. , 1997, Journal of hepatology.

[34]  M. Koziel Immunology of viral hepatitis. , 1996, The American journal of medicine.

[35]  D. V. van Thiel,et al.  Association between reactive oxygen species and disease activity in chronic hepatitis C. , 1996, Free radical biology & medicine.

[36]  V. Carreño,et al.  Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha. , 1994, Digestive diseases and sciences.

[37]  S. Snyder,et al.  Nitric oxide: a physiologic messenger molecule. , 1994, Annual review of biochemistry.